Search Results

Vistagen today announced that company management will present and host one-on-one meetings during the Jefferies Global Healthcare Conference taking place June 5 and 6, 2024 in New York City.

Vistagen today announced that it will present posters at the American Society of Clinical Psychopharmacology Conference in Miami Beach, Florida from May 28 to 31, 2024.

Vistagen announced today that for the second consecutive year it has been recognized by Mental Health America (MHA) for its dedication to promoting mental health and well-being in the workplace.

Vistagen (Nasdaq: VTGN), a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year ended March 31, 2024, and provided a corporate update.

Vistagen today announced that company management will present and host one-on-one meetings during the 2024 RBC Capital Markets Global Healthcare Conference taking place May 14 and 15, 2024 in New York City.

Vistagen today announced that it will present posters detailing clinical trial data for fasedienol, an investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD).

Vistagen today announced that company management will present and host one-on-one meetings during the Stifel 2024 Virtual CNS Days taking place March 19 to 20, 2024.